Answers are grounded in this paper and cite their sources.
The current traditional treatment methods have no apparent advantages in further improving the survival rate of gastric cancer patients. With the rapid development of molecular biology and gene editing technology, a new type of antitumor treatment model - human epidermal growth factor receptor 2 (HER-2), targets chimeric antigen receptor T (CAR-T) cells. Immunotherapy has shown great potential and therapeutic prospects. CAR-T cell immunotherapy has made significant progress in the treatment of solid tumors. However, due to the high heterogeneity of gastric cancer and the complex tumor microenvironment, the immune escape of tumors is caused, and the treatment of gastric cancer still faces many challenges. This article reviews the research progress of HER-2 targeting CAR-T cell immunotherapy for gastric cancer and hopes that it will become a safe and effective treatment for gastric cancer.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2023) studied this question.
Synapse has enriched 4 related papers. Consider them for comparative context: